Wilder Philippe Van
Ecole de Santé Publique, Université Libre de Bruxelles (ULB), Brussels 1050, Belgium.
Pharmaceuticals (Basel). 2021 Apr 10;14(4):352. doi: 10.3390/ph14040352.
We investigated the off-patent biological market in Belgium from a policy maker's perspective, in light of the Belgian pharmaceutical health system. The main barriers relate to a short-term budgetary focus, to the overwhelming innovator's reach and to a concertation model with assessment and appraisal being mixed which results in poorly effective policy measures.
我们从政策制定者的角度，结合比利时的药品卫生体系，对该国非专利生物制品市场进行了调查。主要障碍包括短期预算重点、创新者的巨大影响力，以及评估和评价相结合的协调模式，这导致政策措施效果不佳。
